Simplified Chinese
Minhai Company has signed an agreement with the China Aviation Planning and Design Research Institute.
Release date:
2019-07-03
Author:
Contributed by the General Office
Source:
Abstract
On June 25, 2019, the signing ceremony for the design contract of Minhai Biotechnology’s internationalization industrial base project for novel vaccines was held in the company’s First Conference Room. The ceremony was chaired by Vice President Xiao Qiyou. Attending the event were Company Chairman Du Weimin, General Manager Zheng Haifa, Executive Vice President Liu Jiankai, and other senior leaders, along with Deputy General Manager Liu Zhongwen of the China Aviation Planning & Design Research Institute, Director Wei Shaohui of the Institute of Pharmaceutical Engineering Design under the Institute, and Deputy Director Zhang Wei, among other officials.
At the ceremony, Du Weimin, Chairman of the company, expressed his expectations for the design of the new vaccine‑base project and underscored the critical importance of design in construction. Mr. Du specifically emphasized the need to deliver a high‑quality, exemplary project, with a strong focus on smart technologies, ensuring that the design philosophy is forward‑looking and the planning begins at a high level, fully reflecting the principles of scientific rigor, standardization, intelligence, human‑centricity, and landscape integration. Upon completion, the project will serve as a hub for domestic and international biopharmaceutical R&D institutions and a base for the research and development of global talent, while establishing an overall image for the biopharmaceutical industry as “world‑class and domestically leading.”
Liu Zhongwen, Deputy General Manager of the Aviation Industry Corporation of China’s Research Institute, stated: “The internationalization industrial base project for Minhai Biotechnology’s next-generation vaccines is an outstanding initiative. We will cherish this collaboration opportunity, dispatch our most accomplished team of designers, and, guided by cutting-edge design principles, deliver a world-class project that lives up to the expectations of President Du and all the leaders at Minhai Biotechnology.”
In the presence of all attendees, Chairman Du Weimin and Liu Zhongwen, Deputy General Manager of the Aviation Industry Corporation of China’s Research Institute, signed the Construction Engineering Design Contract on behalf of their respective parties, marking the commencement of the construction phase for the company’s international industrial base project for next-generation vaccines.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account